<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00994721</url>
  </required_header>
  <id_info>
    <org_study_id>T3207</org_study_id>
    <nct_id>NCT00994721</nct_id>
  </id_info>
  <brief_title>A Phase III Study of Pancreatic Cancer</brief_title>
  <official_title>A Randomized Phase III Study of Adjuvant Gemcitabine Versus Gemcitabine Plus Concurrent Chemoradiation in Pancreatic Cancer Underwent Curative Intent (R0 / R1) Resection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Health Research Institutes, Taiwan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chang Gung Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Taipei Veterans General Hospital, Taiwan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mackay Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Taichung Veterans General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cheng-Kung University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kaohsiung Veterans General Hospital.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kaohsiung Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Health Research Institutes, Taiwan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study Design： Adjuvant gemcitabine therapy has been shown to improve recurrence-free survival&#xD;
      in pancreatic cancer underwent curative intent resection. This study is to evaluate whether&#xD;
      combining concurrent chemo-radiotherapy can further improve the recurrence-free survival&#xD;
      benefit of adjuvant gemcitabine chemotherapy in pancreatic cancer underwent curative&#xD;
      resection.&#xD;
&#xD;
      Research Objective and Study End Points&#xD;
&#xD;
        1. Primary endpoint： The primary end point is disease free survival.&#xD;
&#xD;
        2. Secondary endpoints： The secondary end points are to evaluate the overall survival,&#xD;
           local and distant recurrence rate, and impact on quality of life after adjuvant&#xD;
           gemcitabine with or without CCRT in curatively resected pancreatic cancer.&#xD;
&#xD;
      Furthermore, the clinical, pathological and molecular prognostic factors in curatively&#xD;
      resected pancreatic cancers will be evaluated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment plan and Randomization scheme:：&#xD;
&#xD;
      Patients will be randomized after stratification according to pathology report on section&#xD;
      margin, tumor size, lymph node metastasis:&#xD;
&#xD;
      Patients who are randomized to Arm 1 will receive adjuvant chemotherapy started within 4-8&#xD;
      weeks after the surgery, and administered at D1, D8 and D15 every 4 weeks for 6 cycles (6&#xD;
      months). Patients who are allocated to Arm 2 will receive sandwich treatment, which comprised&#xD;
      of the same adjuvant chemotherapy within 4-8 weeks after the surgery for 3 cycles (3 months),&#xD;
      followed by CCRT (start 4-6 weeks after the last dose of 3rd cycle chemotherapy) and then&#xD;
      another 3 cycles of gemcitabine monotherapy.&#xD;
&#xD;
      Statistical Consideration:&#xD;
&#xD;
      We anticipate the 2-year disease free survival will increase from 25% to 40% with the&#xD;
      incorporation of CCRT into the adjuvant treatment for post-operative pancreatic&#xD;
      adenocarcinoma. With a significant level of 0.05, 107 patients will be required for each&#xD;
      treatment arm to reach 80% statistical power. Since the drop out rate is approximately 10%,&#xD;
      265 patients will be enrolled to ensure that we will have 214 (107x2) eligible patients in&#xD;
      this study. We anticipate that we will recruit roughly 67 patients per year, therefore,&#xD;
      patient recruitment will be completed in 4 years.&#xD;
&#xD;
      Randomization scheme:&#xD;
&#xD;
      Histo-/cyto-logically confirmed macroscopic complete resected pancreatic adenocarcinoma&#xD;
&#xD;
        1. The primary end-point is disease free survival.&#xD;
&#xD;
        2. The secondary end-points are overall survival; local and distant control rate, and the&#xD;
           quality of life.&#xD;
&#xD;
        3. The clinical and molecular prognostic factors for overall survival.&#xD;
&#xD;
             -  Radiation fields encompass initial main tumor of pancreas only with a safe margin&#xD;
                of 1cm. Lymph node regions initially involved with tumor confirmed by excision will&#xD;
                be included in the clinical target volume. Elective radiation to uninvolved lymph&#xD;
                nodes will not be given.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The primary end-point is recurrence-free survival.</measure>
    <time_frame>Pancreatic Cancer Disease Committee</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The secondary end-points are overall survival; local and distant control rate, and the quality of life.</measure>
    <time_frame>Pancreatic Cancer Disease Committee</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">147</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>pancreatic cancer</arm_group_label>
    <description>resected pancreatic cancer</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        We anticipate the 2-year disease free survival will increase from 25% to 40% with the&#xD;
        incorporation of CCRT into the adjuvant treatment for post-operative pancreatic&#xD;
        andenocarcinoma. With a significant level of 0.05,107 patients will be required for each&#xD;
        treatment arm to reach 80% statistical power. Since the drop out rate is approximately 10%,&#xD;
        265 patients will be enrolled to ensure that we will have 214(107x2) eligible patients in&#xD;
        this study. We anticipate that we will recruit roughly 67 patients per year, therefore,&#xD;
        patient recruitment will be completed in 4 years.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        A.Eligibility Criteria&#xD;
&#xD;
          1. Patients with pancreatic cancer after curative intent resection.&#xD;
&#xD;
          2. The histology of resected tumor has to be adenocarcinoma.&#xD;
&#xD;
          3. Age 20-75 years.&#xD;
&#xD;
          4. ECOG performance scale 0-1.&#xD;
&#xD;
          5. Patients must have normal organ and marrow function as defined below.&#xD;
&#xD;
          6. The effects of study agents on the developing human fetus at the recommended&#xD;
             therapeutic dose are unknown.&#xD;
&#xD;
          7. to sign a written informed consent.&#xD;
&#xD;
          8. Registered within 6 weeks after surgery.&#xD;
&#xD;
          9. Preoperative abdominal CT or MRI with contrast enhancement.&#xD;
&#xD;
        B.Exclusion Criteria&#xD;
&#xD;
          1. Patients with gross residual, macroscopic positive resection margin or distant&#xD;
             metastases.&#xD;
&#xD;
          2. Patients may not be receiving any other investigational agents.&#xD;
&#xD;
          3. Patients who have had prior chemotherapy or radiotherapy are not eligible.&#xD;
&#xD;
          4. History of allergic reactions.&#xD;
&#xD;
          5. Patients who had non-curable second primary malignancy.&#xD;
&#xD;
          6. Uncontrolled intercurrent illness including.&#xD;
&#xD;
          7. Pregnant women.&#xD;
&#xD;
          8. receiving immuno-suppressive therapy、anti-coagulants.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tsann-Long Hwang, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Chang Gung Memorial Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yu-Wen Tien Tien, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yi-Ming Shyr, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Taipei Veterans General Hospital, Taiwan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pin-Wen Lin, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cheng-Kung University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yu-Lin Lin, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chang-Gung Memorial Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mackay Memorial Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>October 2009</verification_date>
  <study_first_submitted>March 26, 2008</study_first_submitted>
  <study_first_submitted_qc>October 11, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2009</study_first_posted>
  <last_update_submitted>May 3, 2016</last_update_submitted>
  <last_update_submitted_qc>May 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pancreatic Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

